Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Marja
Marja Heiskala, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090305418 | CELL THERAPY METHOD FOR THE TREATMENT OF TUMORS - T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; | 12-10-2009 |
Marja Ilmen, Helsinki FI
Marja Jaattela, Copenhagen DK
| Patent application number | Description | Published |
|---|---|---|
| 20090203721 | USE OF SIRAMESINE IN THE TREATMENT OF CANCER - The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesine for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesine to a patient suffering from cancer. | 08-13-2009 |
Marja Juustila, Lumijoki FI
| Patent application number | Description | Published |
|---|---|---|
| 20100041595 | Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 3c (BMP-3c), nucleotide molecules encoding the protein and host cells expressing the protein. The present invention relates also to the use of said BMP-3c for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the protein are also disclosed. | 02-18-2010 |
| 20100143433 | Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein (BMP), such as BMP-6, containing a heparin binding site and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the bone morphogenetic protein for treating disorders related to bone and cartilage formation. The present invention further relates to osteogenic devices and pharmaceutical compositions containing the protein. | 06-10-2010 |
Marja Juustila, Liminka FI
| Patent application number | Description | Published |
|---|---|---|
| 20090214653 | Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 4 (BMP-4) and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the BMP-4 for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the proteins are also disclosed. | 08-27-2009 |
Marja Karkkaine, Oulu FI
| Patent application number | Description | Published |
|---|---|---|
| 20090199539 | COATING FOR PARTICULATE FILTERS - The invention relates to the coating of a particulate filter used in the treatment of exhaust or waste gases. In the manufacturing of the coating according to the invention, there is used a liquid-based sol, where the average particle size of the contained particles is below 100 nm, preferably below 50 nm. | 08-13-2009 |
Marja Riekkola-Vanhanen, Pori FI
| Patent application number | Description | Published |
|---|---|---|
| 20080241024 | Method for Leaching Metal Sulphide Minerals - The invention relates to a method for the sulphate-based leaching of metal sulphide minerals, such as chalcopyrite, CuFeS | 10-02-2008 |
Marja Salmimaa, Tampere FI
| Patent application number | Description | Published |
|---|---|---|
| 20100277803 | Display Device Having Two Operating Modes - A display device ( | 11-04-2010 |
Marja Sodervall, Ouiu FI
| Patent application number | Description | Published |
|---|---|---|
| 20110015448 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES - The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene. | 01-20-2011 |
Marja Sodervall, Oulu FI
| Patent application number | Description | Published |
|---|---|---|
| 20080207956 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES - The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene. | 08-28-2008 |
| 20080214860 | METHODS FOR THE PREPARATION OF FISPEMIFENE FROM OSPEMIFENE - The present invention concerns a method for preparation of fispemifene by use of ospemifene as a starting material. | 09-04-2008 |
Marja Steenman, Nantes Cedex FR
| Patent application number | Description | Published |
|---|---|---|
| 20110257140 | Biomarkers of Mineralocorticoid Receptor Activation - The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene. | 10-20-2011 |
Marja Tahtinen, Tampere FI
| Patent application number | Description | Published |
|---|---|---|
| 20090252707 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 10-08-2009 |
Marja Tiita, Porvoo FI
| Patent application number | Description | Published |
|---|---|---|
| 20110087058 | DEOXYGENATION OF MATERIALS OF BIOLOGICAL ORIGIN - The present invention relates to a method for the deoxygenation of materials of biological origin and particularly to the removal of oxygen from biomass derived organic compounds with carbon monoxide, to yield linear and branched hydrocarbons suitable as biofuels or as blending stocks or components for biofuels, such as gas, gasoline, diesel fuel and aviation fuel, as well as solvents. The method comprises contacting a feedstock with carbon monoxide in the presence of a catalyst comprising a metal selected from a group consisting of ruthenium, manganese, rhodium, rhenium, osmium, iridium, molybdenum, copper, zinc, palladium, platinum and cobalt, in the presence of water, under alkaline conditions at a temperature from 150 to 350° C. and under a pressure from 0.1 to 150 bar, to produce hydrocarbons. | 04-14-2011 |
| 20110230690 | PROCESS FOR OLIGOMERIZING OLEFINS - A process for oligomerizing olefinic, lower hydrocarbons. The process comprises the steps of feeding a fresh olefinic hydrocarbon feedstock to a reaction zone; contacting the olefinic hydrocarbons of the feedstock with an acidic catalyst in the reaction zone in order to dimerize at least a part of the olefinic hydrocarbons, withdrawing an effluent containing oligomerized olefins from the reaction zone; and conducting the effluent to a separation zone, wherein the oligomerization reaction product is separated from said effluent. According to the invention, the reaction is carried out in homogeneous phase comprising a solvent for olefinic hydrocarbons, maintained at supercritical conditions. By using supercritical carbon dioxide as a solvent deactivation rate of catalyst can be diminished. Carbon dioxide is easy to remove from the product mixture and spent reaction medium can be used for regeneration of the catalyst. | 09-22-2011 |
Marja Tiitta, Porvoo FI
| Patent application number | Description | Published |
|---|---|---|
| 20090270245 | CATALYTIC MATERIALS AND METHOD FOR THE PREPARATION THEREOF - The invention is related to catalytic materials and particularly to mesoporous molecular sieves embedded with a zeolite, which are thermally stable at a temperature of at least 900° C., and to a method for the preparation of the catalytic materials. Said catalytic materials are suitable for applications in the field of hydrocarbon processing. | 10-29-2009 |
| 20100298616 | METHOD FOR THE MANUFACTURE OF BRANCHED SATURATED HYDROCARBONS - The invention relates to a method for the manufacture of branched saturated hydrocarbons, said method comprising the steps where a feed comprising olefins having at least 10 carbons is simultaneously hydrogenated and isomerized in the presence of hydrogen at a temperature of 100-400° C., under hydrogen partial pressure of 0.01-10 MPa, in the presence of a catalyst comprising a metal selected from the metals of Group VIIIb of the Periodic table of Elements, a molecular sieve selected from ten member ring molecular sieves, twelve member ring molecular sieves and mesoporous molecular sieves embedded with zeolite, and a carrier, to yield branched saturated hydrocarbons. | 11-25-2010 |
Marja Van Meijer, Amsterdam NL
| Patent application number | Description | Published |
|---|---|---|
| 20100184671 | Binding molecules for the treatment of myeloid cell malignancies - Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases. | 07-22-2010 |